CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock, Par Value	Additional Paid in Capital	Accumulated Deficit	Non-Controlling interest
Balance at Dec. 31, 2013	$ 55,348,000	$ 10,000	$ 226,515,000	$ (171,177,000)
Balance (in shares) at Dec. 31, 2013	90,182,115	90,182,115
Increase (Decrease) in Stockholders' Equity
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement	22,795,000		22,795,000
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement, via registered direct offerings, and via private placements (in shares)		3,917,149
Fees and expenses related to controlled equity sales	(629,000)		(629,000)
Stock based compensation expense	2,264,000		2,264,000
Exercise of stock options	36,000		36,000
Exercise of stock options (in shares)		9,999
Private placement of ContraVir common stock	3,224,000		3,224,000
Fees and expenses associated with ContraVir Private Placement	(15,000)		(15,000)
Fair value of ContraVir warrants issued in connection with private placement	(880,000)		(880,000)
Noncontrolling interest of ContraVir	(1,622,000)				(1,622,000)
Distribution of ContraVir common stock to Synergy shareholders	(1,740,000)		(1,740,000)
Elimination of noncontrolling interest of ContraVir upon distribution	1,622,000				1,622,000
Net loss for the period	(42,145,000)			(42,145,000)
Balance at Jun. 30, 2014	$ 38,258,000	$ 10,000	$ 251,570,000	$ (213,322,000)
Balance (in shares) at Jun. 30, 2014	94,109,263	94,109,263